H1 2020 Financial Information
- Cash and cash equivalents at €52.2m as at June 30, 2020
Daix (France), July 6, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of June 30, 2020.
As of June 30, 2020, Inventiva’s cash and cash equivalents stood at €52.2 million compared to €46.9 million as of March 31, 2020 and €35.8 million as of December 31, 2019.
Inventiva’s net cash flow amounted to €16.4 million in the six months ended June 30, 2020 compared to (€19.6) million in the first half of 2019. Net cash used in operating activities was (€10.7) million and (€18.7) million in the first half of 2020 and 2019, respectively. Net cash provided by (used in) financing activities was €28.1 million and (€0.1) million in the first half of 2020 and 2019, respectively.
The Company believes that its cash and cash equivalents as of June 30, 2020 will be sufficient to fund its operating activities into the third quarter of 2021.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012). www.inventivapharma.com
Chairman & CEO
+33 3 80 44 75 00
Yannick Tetzlaff / Tristan Roquet Montegon /
+33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank
+1 415 513 1284
This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, or that candidates will receive the necessary regulatory approvals. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates.Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release.Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the Universal Registration Document filed with the Autorité des marchés financiers (AMF) on June 19, 2020, available on the websites of Inventiva (www.inventivapharma.com) and AMF (www.amf-france.org), for additional information in relation to such factors, risks and uncertainties.
Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS14.8.2020 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Kommuninvest Bonds, 2020-08-18 Maturity dateLoanISIN codeCouponVolume, SEK million2022-06-012206SE00092694180.25 %500 +/- 2502023-11-132311SE00109482401.00 %500+/- 2502025-05-12 2505 SE0011414010 1.00 % 500+/- 250 2026-11-12 2611 SE0012569572 1.00 % 500+/- 250 Maximum volume 2 000 million in total Settlement date 2020-08-20 Bids have to be entered by 11.00 on AUG 18, 2020 Highest permitted bid volume: 500 SEK million in issue 2206, 2311, 2505, and 2611. Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 11.15 (CEST) ON AUG 18, 2020 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
CONDITIONS FOR RIKSBANK BID PROCEDURES SEK GOVERNMENT BONDS14.8.2020 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2020-08-21 Maturity dateLoanISIN codeCouponVolume, SEK million2028-05-121060SE00094963670.75 %1000 +/- 2502031-05-121062 SE00139353190.125 1000 +/- 250 Settlement date 2020-08-25 Bids have to be entered by 10.00 on AUG 21, 2020 Highest permitted bid volume: 1000 SEK million in issue SGB 1060 and 1000 SEK million in issue SGB 1062 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON AUG 21, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
SEK CREDIT OPERATION ANNOUNCEMENT14.8.2020 16:20:00 CEST | Press release
SEK CREDIT OPERATION ANNOUNCEMENT 2020-08-18 Transaction type:SEK CreditTender date:2020-08-18Time for submission of bids:11.00-11.30 (CEST)Payment date:2020-08-18 (at 3 pm)Maturity date:2020-11-16Duration:13 weeks. For credit in consequence of the auction on 18 August 2020, the maturity is however 12 weeks and 6 daysOffered volume:UnlimitedLowest accepted bid volumeSEK 50 millionMaximum number of bids from each participant: 1RateRepo rate Transaction type:SEK CreditTender date:2020-08-18Time for submission of bids:11.00-11.30 (CEST)Payment date:2020-08-18 (at 3 pm)Maturity date:2021-02-15Duration:26 weeks. For credit in consequence of the auction on 18 August 2020, the maturity is however 25 weeks and 6 days. Offered volume:UnlimitedLowest accepted bid volumeSEK 50 millionMaximum number of bids from each participant: 1RateRepo rate All monetary counterparties are invited to submit volume bids to the Riksbank, tel + 46 8 6966970 by 11.30 am on August 18, 2020. Confirmation of bids to e
CONDITIONS FOR RIKSBANK BID PROCEDURES SEK COVERED BONDS14.8.2020 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Covered Bonds, 2020-08-20 Maturity dateLoanISIN codeCouponVolume, SEK million2025-09-175535 SE00133584131.00 %1,000 +/- 5002024-12-18579 SE00121936211.00 %1,000 +/- 500 2024-12-031589SE00116433861.50 %1,000 +/- 5002025-06-18195SE00135460661.00 %1,000 +/- 5002024-12-182412SE00126218521.00 %400 +/- 2502025-09-17518SE00113092441.25 %400 +/- 2502025-06-11146SE00133815711.00 %400 +/- 250 Settlement date 2020-08-24 Bids have to be entered by 10.00 on AUG 20 2020 Highest permitted bid volume: 1,000 SEK million in issue 5535 1,000 SEK million in issue 579 1,000 SEK million in issue 1589 1,000 SEK million in issue 195 400 SEK million in issue 2412 400 SEK million in issue 518 400 SEK million in issue 146 Maximum volume 5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON AUG 20, 2020. For more information, please conta
NEXSTIM ABP:S HALVÅRSRAPPORT 1/1–30/6 2020 (OREVIDERAD)14.8.2020 14:00:00 CEST | Pressemelding
Företagsmeddelande, Insiderinformation, Helsingfors 14 augusti 2020 kl. 15.00 (EEST) NEXSTIM ABP:S HALVÅRSRAPPORT 1/1–30/6 2020 (OREVIDERAD) Viktiga händelser januari–juni 2020 Vi fokuserade på att minimera effekterna av covid-19-pandemin och utforma en ny strategi. Med tanke på den svåra affärsmiljön gjorde vi goda framsteg genom att sälja fyra nya NBS-system, tre i USA och ett i EU och installera fem nya NBT®-system på kliniker i USA och Europa för behandling av egentlig depression. Halvåret 1/1–30/6 2020 var det bästa någonsin för bolaget, med avseende på omsättningen, rörelseresultatet och räkenskapsperiodens resultat. Bolagets totala omsättning under första halvåret var 1,6 miljoner euro (H1 2019: 1,2 mn euro), rörelseresultatet var -1,8 miljoner euro (H1 2019: -3,4 mn euro) och räkenskapsperiodens resultat var -1,2 miljoner euro (H1 2019: -3,7 mn euro). Under första halvåret ökade omsättningen för NBS (med 47 %) till 0,9 miljoner euro (H1 2019: 0,2 mn euro) och för NBT (med 18 %)
NEXSTIM PLC HALF-YEARLY REPORT 1 JANUARY – 30 JUNE 2020 (UNAUDITED)14.8.2020 14:00:00 CEST | Press release
Company announcement, Inside Information, Helsinki, 14 August 2020 at 15:00 (EEST) NEXSTIM PLC HALF-YEARLY REPORT 1 JANUARY – 30 JUNE 2020 (UNAUDITED Highlights, January – June 2020 Focused on minimizing the effect of COVID-19 pandemic as well as updating company strategy. Considering the difficult business environment, good progress with four new NBS systems sold, three in the US one in the EU and a total of five new NBT® systems installed to clinics in the US and Europe, across multiple sites, for the treatment of Major Depressive Disorder (MDD) January 1 – June 30, 2020 was historically the Company’s best first half to date when measured by net sales, operating result and result for the period. The total net sales in the first half was EUR 1.6 million (2019 H1: EUR 1.2 million), operating result EUR -1.8 million (2019 H1: -3.4 million) and result for the period EUR -1.2 million (2019 H1: EUR -3.7 million) NBS net sales grew by 47% in H1 to EUR 0.9 million (2019 H1: EUR 0.6 million)